Sareum Holdings PLC
RYH0
Company Profile
Business description
Sareum Holdings PLC is engaged in drug discovery and development. The company is focused on cancer and autoimmune diseases and licensing them to pharmaceutical and biotechnology companies. The company's drug pipeline includes SDC-1801 for autoimmune diseases, SDC-1802 for cancers, SRA737 targeting solid tumors among others.
Contact
Langford Arch, London Road
Unit 2a, Pampisford
CambridgeCambridgeshireCB22 3FX
GBRT: +44 1223497700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
5
Stocks News & Analysis
stocks
Going into earnings, is Alphabet stock a buy, a sell, or fairly valued?
From AI integration to capital expenditure increases, here’s what we expect in Alphabet’s earnings report.
stocks
ASX energy share remains cheap despite strong outlook
Santos reports a solid quarter on the back of higher commodity prices - yet the shares look undervalued.
stocks
Moated AI-proof tech play hiding in the ASX 100
ChatGPT and large language models should be a tailwind for this company.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,990.80 | 20.60 | 0.23% |
| CAC 40 | 8,160.83 | 3.01 | 0.04% |
| DAX 40 | 24,189.00 | 60.02 | 0.25% |
| Dow JONES (US) | 49,230.71 | 79.61 | -0.16% |
| FTSE 100 | 10,343.14 | 35.94 | -0.35% |
| HKSE | 25,925.65 | 52.42 | -0.20% |
| NASDAQ | 24,836.60 | 398.10 | 1.63% |
| Nikkei 225 | 60,537.36 | 821.18 | 1.38% |
| NZX 50 Index | 12,874.94 | 9.99 | -0.08% |
| S&P 500 | 7,165.08 | 0.00 | 0.00% |
| S&P/ASX 200 | 8,766.40 | 17.20 | 0.20% |
| SSE Composite Index | 4,086.34 | 6.44 | 0.16% |